HomepagePTKFY • OTCMKTS
add
PT Kalbe Farma Unsponsored Indonesia ADR
Vorige slotkoers
$Â 14,30
Jaar-range
$Â 11,44 - $Â 21,16
Beurswaarde
56,17Â bln. IDR
Gem. volume
68,00
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (IDR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 8,91Â bln. | 12,62% |
Bedrijfskosten | 2,60Â bln. | 14,02% |
Netto inkomsten | 656,41Â mld. | 14,50% |
Netto winstmarge | 7,37 | 1,66% |
Winst per aandeel | 14,44 | 16,36% |
EBITDA | 1,05Â bln. | 16,48% |
Effectief belastingtarief | 24,06% | — |
Balans
Totale activa
Totale passiva
| (IDR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 4,20Â bln. | -2,69% |
Totale activa | 30,10Â bln. | 4,70% |
Totale passiva | 5,30Â bln. | 9,51% |
Totaal aandelenvermogen | 24,80 bln. | — |
Uitstaande aandelen | 45,32 mld. | — |
Koers-boekwaardeverhouding | 0,03 | — |
Rendement op activa | 7,14% | — |
Rendement op kapitaal | 8,47% | — |
Kasstroom
Nettomutatie in liquide middelen
| (IDR) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 656,41Â mld. | 14,50% |
Operationele kasstroom | 875,16Â mld. | -24,23% |
Kasstroom uit beleggingen | -258,39Â mld. | -46,28% |
Kasstroom uit financiering | -396,06Â mld. | 5,95% |
Nettomutatie in liquide middelen | 245,07Â mld. | -49,14% |
Vrije kasstroom | 569,54Â mld. | -24,75% |
Over
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Opgericht
10 sep 1966
Website
Werknemers
12.784